Скачать или смотреть CAR T-cell therapy in myasthenia gravis: advances and future perspectives

Ali Habib, MD, University of California, Irvine, comments on the potential of CAR-T therapy in myasthenia gravis. Dr Habib notes that CAR-T therapy has the potential to affect multiple pathways in disease pathophysiology and be a one-time treatment, which is advantageous over currently available options. These agents have shown promising results in terms of safety and tolerability in early phase trials, as well as depth and durability of response. Dr Habib emphasizes the importance of patient selection, highlighting that patients who have not had an adequate response to conventional therapies may be suitable for CAR-T clinical trials. This discussion took place at the 7th International Workshop on CAR-T and bispecifics (iwCAR-T) 2025 held in Miami, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.